What Is Central Sensitization, and Why Does It Explain Chronic Pain?

In 1983, Clifford Woolf published a paper that changed how pain researchers understood persistent pain. He demonstrated that injury to peripheral tissue could produce lasting changes in the excitability of neurons in the spinal cord, changes that persisted after the peripheral input was removed [1]. The term for this process is central sensitization, and it has become the most robust mechanistic explanation for conditions where pain persists without ongoing tissue damage.

The concept is straightforward in principle, though the neuroscience beneath it is not. In a healthy nervous system, pain signals travel from peripheral nerves through the dorsal horn of the spinal cord to the brain, and descending pathways from the brainstem modulate those signals, usually dampening them. In central sensitization, both halves of this system change: the ascending signals get louder, and the descending inhibition gets quieter [2].

This is not a metaphor. The “louder” ascending signals are neurons that have been measurably altered in their excitability, and the “quieter” descending inhibition is a measurable reduction in the function of serotonergic and noradrenergic pathways from the brainstem. The machinery of pain processing has been recalibrated, and the recalibration persists independently of whatever triggered it.

What Happens at the Spinal Cord Level

The dorsal horn is where peripheral pain signals first enter the central nervous system. Under normal conditions, the neurons here respond proportionally to the input: a mild stimulus produces a mild signal, a strong stimulus produces a strong one. In central sensitization, this proportionality breaks down.

Three measurable changes occur. First, wind-up: repeated stimulation of C-fibers (the slow, burning-pain fibers) causes dorsal horn neurons to fire progressively harder, even though the input stays the same. This temporal summation is mediated by NMDA receptor activation. Under normal conditions, a magnesium ion blocks the NMDA receptor channel; cumulative depolarization from repeated stimulation removes this block, allowing calcium influx that amplifies the neuron’s response and triggers intracellular signaling cascades that further increase excitability [2].

Second, reduced thresholds: neurons begin responding to stimuli that would previously have been below their activation point. Touch fibers that normally signal innocuous contact begin activating pain pathways. This is the mechanism behind allodynia, the painful response to stimuli that should not be painful.

Third, expanded receptive fields: neurons that previously responded only to input from a small area of the body begin responding to input from a wider area [2]. This expansion is one reason chronic pain often spreads beyond its original site: the dorsal horn neurons that initially responded only to signals from, say, the lower back begin responding to signals from the hip, the thigh, or the upper back.

The result is that the same touch, pressure or temperature that would have been felt as neutral or mildly uncomfortable in an unsensitized system now registers as pain. This is not a failure of perception. It is an accurate perception of an abnormal signal.

What Happens in the Brain

Central sensitization is not limited to the spinal cord. Functional imaging studies show that people with chronic pain conditions, particularly fibromyalgia, show altered connectivity in brain regions involved in pain processing, including the insula, anterior cingulate cortex, and prefrontal cortex [3]. The insula integrates sensory information with emotional context; the anterior cingulate cortex processes the unpleasantness of pain; the prefrontal cortex is involved in the cognitive evaluation of threat. Changes in how these regions communicate alter not just the intensity of the pain signal but its emotional and cognitive character.

Descending inhibitory pathways, which normally act as a volume control on pain transmission, show reduced function. These pathways originate in the brainstem and use serotonin and norepinephrine to dampen signaling in the dorsal horn. When they are functioning well, they filter out low-level noise and keep pain signals proportionate. When their function is reduced, the filtering fails, and signals that should be suppressed get through. The net effect is that the system that should be turning the signal down is not doing its job.

This is not a psychological state. It is a measurable neurobiological finding. Quantitative sensory testing can demonstrate lowered pressure-pain thresholds, increased temporal summation, and impaired conditioned pain modulation in people with central sensitization, and these findings are consistent across multiple chronic pain populations [4]. Conditioned pain modulation, which tests whether one pain stimulus inhibits another (a proxy for descending inhibition), is reliably impaired in fibromyalgia, providing direct evidence that the top-down volume control is not working normally.

Central Sensitization and Fibromyalgia

Fibromyalgia is the condition most consistently associated with central sensitization. The widespread pain, allodynia (pain from normally non-painful stimuli), hyperalgesia (increased pain from normally painful stimuli), fatigue, and cognitive symptoms of fibromyalgia are all consistent with a nervous system that has become sensitized to a broad range of inputs [5].

Muhammad Yunus proposed the term “central sensitivity syndromes” to describe a group of overlapping conditions, including fibromyalgia, irritable bowel syndrome, and tension-type headache, that share the common feature of augmented central pain processing [5]. The clinical overlap between these conditions (many people with fibromyalgia also have IBS and headaches) supports this grouping. A person with fibromyalgia who also experiences irritable bowel symptoms and tension headaches is not unlucky enough to have three separate conditions; they have one underlying mechanism, central sensitization, producing symptoms in multiple systems.

This framework replaced an older model in which fibromyalgia was understood as either a peripheral muscle disorder or a primarily psychological condition. Both of those models were wrong. Fibromyalgia involves real, measurable changes in central pain processing, and those changes produce real suffering. The dismissal that many fibromyalgia patients have experienced from clinicians who treated it as a psychosomatic complaint was, in addition to being harmful, scientifically inaccurate.

The overlap between central sensitivity syndromes also has implications for treatment. If fibromyalgia, IBS, and tension headache share a common central mechanism, then treatments that modify central sensitization (exercise, medications like duloxetine that enhance descending inhibition, pain neuroscience education) might improve multiple conditions simultaneously. Some clinical evidence supports this: patients who exercise regularly for fibromyalgia sometimes report improvement in their IBS symptoms as well. The shared mechanism suggests that treating the sensitization, rather than each symptom independently, may be the more efficient approach.

Why This Matters for Treatment

Understanding central sensitization changes the treatment conversation in two specific ways. First, it explains why treatments aimed at peripheral tissue (anti-inflammatory drugs, localized procedures) often have limited effect in fibromyalgia: the amplification is happening centrally, not peripherally. A person with fibromyalgia who takes ibuprofen for widespread pain is targeting a mechanism that is not the primary driver of their symptoms. Second, it makes sense of treatments that do work: duloxetine increases descending serotonergic and noradrenergic inhibition, pregabalin reduces excitatory neurotransmitter release at the spinal cord level, and exercise has been shown to activate descending pain inhibition pathways.

Understanding the mechanism is itself part of the treatment. Pain neuroscience education, which teaches patients how pain processing works and why sensitization produces the symptoms they experience, has evidence for reducing catastrophizing and improving function, though the evidence for reducing pain intensity scores is less consistent.

Nijs and colleagues have proposed that identifying central sensitization in individual patients could guide treatment selection, a step toward what they describe as precision medicine for chronic pain [3]. A patient whose quantitative sensory testing shows enhanced temporal summation and impaired conditioned pain modulation might be directed toward centrally acting medications and pain neuroscience education, rather than spending months on treatments targeting peripheral structures. This is a plausible direction, but not yet standard clinical practice.

What Remains Uncertain

Several important questions remain open. The trigger for central sensitization in fibromyalgia is not well understood: some patients develop it after a peripheral injury, some after an infection, and some without an identifiable precipitant. Whether there is a genetic predisposition to developing sensitization, and which genes are involved, is an area of active research without definitive answers.

The degree to which sensitization is reversible in established fibromyalgia is unclear, though the evidence for exercise and medication suggests meaningful modification is possible. The relationship between central sensitization and psychological factors (depression, anxiety, catastrophizing) is bidirectional and incompletely mapped: each worsens the other, but the causal pathways are not fully defined. Catastrophizing increases the brain’s threat assessment, which amplifies pain, which increases catastrophizing; untangling cause from effect in this loop is methodologically difficult.

Finally, the Central Sensitization Inventory, while clinically useful as a screening tool, measures symptom overlap rather than the mechanism itself [6], and a reliable, accessible biomarker for central sensitization remains an unmet clinical need. Quantitative sensory testing can detect markers of sensitization, but it requires specialized equipment and trained operators, making it impractical for routine clinical use. Until a more accessible tool is available, identifying central sensitization in clinical practice will continue to rely on clinical judgment and symptom patterns rather than direct measurement.

Getting support for chronic pain. Chronic pain, including fibromyalgia, is a complex medical condition that deserves proper clinical attention. A GP, rheumatologist or pain specialist can help develop a management plan. The American Chronic Pain Association (theacpa.org) and the National Fibromyalgia Association (fmaware.org) have patient resources and practitioner directories.